Testicular carcinoma is a leading cause of cancer-related deaths in adult males between the ages of 20 and 35. Cis-Diamminedichloroplatinum (II) (i.e., CDDP) is currently being used investigatively in combination chemotherapy for the treatment of this disease. This article reviews the literature to date on CDDP and its application in testicular cancer. Individual CDDP parameters (e.g., chemistry, mechanism of action, effectiveness and clinical use, adverse effects, dosage, administration and distribution) are discussed.
Get full access to this article
View all access options for this article.
References
1.
EinhornL. H.: General Principles of Cancer Chemotherapy, Conn. Med.40: 159–168 (Mar.) 1976.
2.
RosenbergB.VanCampL.KrigasT.: Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode, Nature (London)205: 698–699 (Feb.) 1965.
3.
LehF. K. V.WolfW.: Platinum Complexes: A New Class of Antineoplastic Agents, J. Pharm. Sci.65: 315–327 (Mar.) 1976.
4.
RobertsJ. J.PascoeJ. M.: Crosslinking of Complementary Strands of DNA in Mammalian Cells by Antitumour Platinum Compounds. Nature (London)235: 282–284 (Feb.) 1972.
5.
MunchausenL. L.RahnR. O.: Biologic and Chemical Effects of Cis-dichlorodiammineplatinum (II) (NSC-119875) on DNA, Cancer Chemother. Rep.59: 643–646 (May/June) 1975.
6.
HowieJ. A.GaleG. R.: Cis-Dichlorodiammine-platinum (II): Persistant and Selective Inhibition of Deoxyribonucleic Acid Synthesis in Vivo, Biochem. Pharmacol.19: 2757–2762 (Oct.) 1970.
7.
RosenbergB.: Possible Mechanisms for the Antitumor Activity of Platinum Coordination Complexes, Cancer Chemother. Rep.59: 589–598 (May/June) 1975.
8.
DavidsonJ. P.: “Platinum-Pyrimidine Blues” and Related Complexes: A New Class of Potent Antitumor Agents, Cancer Chemother. Rep.59: 287–300 (Mar./Apr.) 1975.
SchaeppiU.: Cis-Dichlorodiammineplatinum (II) (NSC-119875) Preclinical Toxicologic Evaluation of Intravenous Injection in Dogs, Monkeys and Mice, Toxicol. Appl. Pharmacol.25: 230–241 (June) 1973.
11.
EinhornL. H.DonohueJ. P.: Improved Chemotherapy in Disseminated Testicular Cancer, J. Urol.117: 65–69 (Jan.) 1977.
12.
HigbyD. J.WallaceH. J.AlbertD.HollandJ. F.: Diamminodichloroplatinum in the Chemotherapy of Testicular Tumors, J. Urol.112: 100–104 (July) 1974.
13.
MacKayE. N.SellersA. H.: A Statistical Review of Malignant Testicular Tumors Based on the Experience of the Ontario Cancer Foundation Clinics, 1938 to 1961, Can. Med. Assoc. J.94: 889 (Apr. 23) 1966.
14.
LippmanA. J.: Clinical Trials of Cis-Diammine-dichloroplatinum (NSC-119875), Cancer Chemother. Rep.57: 191–200 (Apr.) 1973.
15.
HillJ. M.: Clinical Experience with Cis-Plati-nous Diamminodichloride (PDD)In Advances in Antimicrobial and Antineoplastic Chemotherapy, Vol. 2, University Park Press, Baltimore, MD, p. 255, 1972.
16.
HigbyD. J.WallaceJ. H.AlbertD. H.HollandJ. F.: Diamminodichloroplatinum: A Phase I Study Showing Responses in Testicular and Other Tumors, Cancer (Philadelphia)33: 1219–1225 (May) 1974.
17.
HigbyD. J.WallaceJ. H.Jr.HollandJ. F.: Cis-Diamminedichloroplatinum (NSC-119875): A Phase I Study, Cancer Chemother. Rep.57: 459–463 (Nov./Dec.) 1973.
18.
HillJ. M.LoebE.MacLellamA.HillN. O.KahnA.KingJ. J.: Clinical Studies of Platinum Coordination Compounds in the Treatment of Various Malignant Diseases, Cancer Chemother. Rep.59: 647–659 (May/June) 1975.
19.
GottliebJ. A.DrewinkoB.: Review of the Current Clinical Status of Platinum Coordination Complexes in Cancer Chemotherapy, Cancer Chemother. Rep.59: 621–628 (May/June) 1975.
20.
HandelsmanH.GoldsmithM. A.BroderL. E.CarterS. K.SlavikM.: Cis-Platinum (II) Diamminedichloride (NSC-119875), Clinical Brochure, Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment — National Cancer Institute (Aug.) 1974.
21.
DeContiR. C.ToftnessB. R.LangeR. C.CreaseyW. A.: Clinical and Pharmacological Studies with Cis-Diamminedichloroplatinum (II), Cancer Res.33: 1310–1315 (June) 1973.
22.
HardakerW. T.StoneR. A.McCoyR.: Platinum Nephrotoxicity, Cancer (Philadelphia)34: 1030–1032 (Oct.) 1974.
23.
LangeR. C.SpencerR. P.HarderH. C.: Synthesis and Distribution of a Radiolabeled Antitumor Agent: Cis-Diamminedichloroplatinum (II), J. Nucl. Med.13: 328–330 (May) 1972.
24.
SmithP. H. S.TaylorD. M.: Distribution and Retention of the Antitumor Agent 195m Pt-Cis-Dichlorodiammineplatinum (II) in Man, J. Nucl. Med.15: 349–351 (May) 1974.
25.
LitterstC. L.GramT. E.DedrickR. L.LeroyA. F.GuarinoA. M.: Distribution and Disposition of Platinum Following Intravenous Administration of Cis-Diamminedichloroplatinum (II) (NSC-119875) to Dogs, Cancer Res.36: 2340–2344 (July) 1976.
26.
TalleyR. W.O'BryanR. M.GuttermanJ. U.: Clinical Evaluation of Toxic Effects of Cis-Diamminedichloroplatinum (NSC-119875) — Phase I Clinical Study, Cancer Chemother. Rep.57: 465–471 (Nov./Dec.) 1973.
27.
RossofA. H.SlaytonR. E.PerliaC. P.: Preliminary Clinical Experience with Cis-Diamminedichloroplatinum (II) (NSC-119875)Cancer (Philadelphia)30: 1451–1456 (Dec.) 1972.
28.
HaddowJ. E.LesterR.: Mechanism of Action of Spironolactone in Preventing Mercury Toxicity, Gastroenterology64: 159 (Jan.) 1973.
29.
DrewinkoB.BrownB. W.GottliefJ. A.: The Effect of Cis-Diamminedichloroplatinum (II) on Cultured Human Lymphoma Cells and Its Therapeutic Implications, Cancer Res.33: 3091–3095 (Dec.) 1973.
PielI. J.MeyerD.PerliaC. P.WolfeV. I.: Effects of Cis-Diamminedichloroplatinum (NSC-119875) on Hearing Function in Man, Cancer Chemother. Rep.58: 871–875 (Nov./Dec.) 1974.
KhanA.HillJ. M.GraterW.LoebE.MacLellamA.HillN.: Atopic Hypersensitivity to Cis-Dichlorodiammineplatinum (II) and Other Platinum Complexes, Cancer Res.35: 2766–2770 (Oct.) 1975.
